StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Updated Price Target from Clarus (Noel Atkinson)

<< Previous

Bullboard Posts

Next >>

Comment by NewToInvesting7on Dec 09, 2020 10:19am

196 Views

Post# 32066695

RE:Updated Price Target from Clarus (Noel Atkinson)

One other thing that I failed to mention - The Dec. 8 Morningstar report on SZLS, currently shows a Fair Value of a share to be C$1.19.

(Apologies for the follow-up, but I thought that I could edit my post to add the adove. Clearly I was worng).

NewToInvesting7 wrote: Not sure whether this has been posted yet, but thought that I would make mention of Noel's change in price target for SZLS.

The TD Webbroker website is showing that Noel Atkinson has maintained his buy rating for SZLS, and has change his price target on 12/08/2020 (Dec. 8), from C$4 to C$5.13

Cheers